Trials / Unknown
UnknownNCT01828008
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Han weidong · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Detailed description
Autologous CIK transfusion within 3 days post CD20 antibody treatment.
Conditions
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2013-04-10
- Last updated
- 2013-04-10
Source: ClinicalTrials.gov record NCT01828008. Inclusion in this directory is not an endorsement.